2001
Tolerability Profile of Atypical Antipsychotics in Children and Adolescents
Stigler K, Potenza M, McDougle C. Tolerability Profile of Atypical Antipsychotics in Children and Adolescents. Pediatric Drugs 2001, 3: 927-942. PMID: 11772153, DOI: 10.2165/00128072-200103120-00005.Peer-Reviewed Original ResearchConceptsUse of clozapineExtrapyramidal symptomsAtypical antipsychoticsBodyweight gainTolerability profileGlucose intoleranceBlood glucoseReceptor profileRisk of EPSAdverse effectsCommon adverse effectsLiver function studiesTreatment-refractory diseasePotential treatment optionReceptor interaction profilesOnset of maniaLack of evidenceQTc prolongationBaseline electrocardiogramTreatment optionsSeizure riskCardiovascular illnessClose monitoringClozapineAntipsychoticsReply to Comments on "Olanzapine Treatment of Children, Adolescents, and Adults With Pervasive Developmental Disorders: An Open-Label Pilot Study"
Potenza M, McDougle C. Reply to Comments on "Olanzapine Treatment of Children, Adolescents, and Adults With Pervasive Developmental Disorders: An Open-Label Pilot Study". Journal Of Clinical Psychopharmacology 2001, 21: 246-247. PMID: 11270929, DOI: 10.1097/00004714-200104000-00024.Peer-Reviewed Original Research
1999
Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders
Potenza M, Holmes J, Kanes S, McDougle C. Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders. Journal Of Clinical Psychopharmacology 1999, 19: 37-44.. PMID: 9934941, DOI: 10.1097/00004714-199902000-00008.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical Global Impression ScaleWeight gainTolerability of olanzapineLiver function abnormalitiesExtrapyramidal side effectsGlobal Impression ScaleGlobal improvement itemTreatment of childrenSignificant adverse effectsDevelopmental disordersSelf-injurious behaviorClinical respondersOlanzapine treatmentFunction abnormalitiesDaily doseOverall symptomsPatient populationImpression ScalePrincipal diagnosisMotor restlessnessProspective fashionWeek 4Related symptomsSide effects
1998
Olanzapine Augmentation of Fluoxetine in the Treatment of Refractory Obsessive-Compulsive Disorder
Potenza M, Wasylink S, Longhurst J, Epperson C, McDougle C. Olanzapine Augmentation of Fluoxetine in the Treatment of Refractory Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 1998, 18: 423-424.. PMID: 9790164, DOI: 10.1097/00004714-199810000-00014.Peer-Reviewed Original ResearchOlanzapine Augmentation of Fluoxetine in the Treatment of Trichotillomania
POTENZA M, WASYLINK S, EPPERSON C, MCDOUGLE C. Olanzapine Augmentation of Fluoxetine in the Treatment of Trichotillomania. American Journal Of Psychiatry 1998, 155: 1299a-1300. PMID: 9734562, DOI: 10.1176/ajp.155.9.1299a.Peer-Reviewed Original Research